Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Levoca – page 15

194 clinical trials in Levoca, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Levoca at a glance
194
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

194 trials in Levoca

Open in trial search

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Crohn's disease

Not recruiting

Long-term study of upadacitinib tablets for adults with Crohn's disease

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Effectiveness and Safety of EDP-938 for Adults with High-Risk Respiratory Syncytial Virus (RSV) Infection

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Zelicapavir
  • Sponsor:Enanta Pharmaceuticals Inc.

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Obesity+1

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Related Health Issues

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Levoca

What the registry says about research in the country

01 Cardiovascular Research

Innovative research focusing on atherosclerotic cardiovascular disease (ASCVD) treatment optimization. Studies aim to evaluate new therapeutic approaches for patients whose current lipid-modifying treatments aren't providing sufficient results.

  • Cardiovascular event prevention
  • Lipid management therapy
  • Arterial plaque reduction

Research emphasizes improving outcomes for patients with advanced cardiovascular conditions.

02 Stroke Prevention Studies

Comprehensive research into ischemic stroke prevention, particularly focusing on innovative treatments for patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-stroke treatment optimization
  • Blood clot prevention
  • Antiplatelet therapy enhancement

Studies evaluate new oral medications against established treatments to improve patient outcomes.

03 Cardiac Rhythm Management

Advanced research targeting atrial fibrillation complications, with a focus on preventing stroke and systemic embolism in at-risk patients.

  • Stroke prevention in AF patients
  • Bleeding risk management
  • Comparative treatment efficacy

Investigations aim to establish superior treatment options with improved safety profiles.

04 Neurological Disorders

Critical research addressing refractory status epilepticus (RSE), evaluating new therapeutic interventions combined with standard care protocols.

  • Emergency seizure management
  • Treatment resistance
  • Novel therapeutic approaches

Studies focus on developing more effective treatments for severe seizure conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.